Business
SOPHiA GENETICS Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study
Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to
About this update from Sophia Genetics Sa
[{"type":"text","content":"Study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer\n Since study launch, 12 sites across 5 countries have already signed up for participation\n\n\nBOSTON and LAUSANNE, Switzerland, Jan. 11, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (NASDAQ: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today strong traction in the launch phase of their DEEP-Lung-IV clinical study (NCT04994795). Since officially launching last month, 12 sites across 5 countries have already signed up for participation in the study.\n\n \n \n \n \n \n \n\n \nDespite the clinical promise of immunotherapy, significant challenges remain as the majority of non-small cell lung cancer (NSCLC) patients fail to respond to immune checkpoint inhibitors. Today, PD-L1 is the only standard predictive biomarker for immune checkpoint inhibitor efficacy, however it remains a very suboptimal biomarker with several well-characterized issues limiting its clinical utility. Thus, there is an urgent need to discover new predictive biomarkers of response to immunotherapy. SOPHiA GENETICS' DEEP-Lung-IV clinical study leverages deep learning-enabled analysis of the aggregation of real-world multimodal data (including genomics, radiomics and clinical data) to identify and validate predictive signatures associated with response to immunotherapy and prognosis of patients with metastatic (stage IV) NSCLC. Such signatures could help identify patients that are likely to benefit from immunotherapy versus those that are not, as well as stratify patients according to risk, helping clinicians make more informed therapeutic decisions for their patients and supporting biopharma to ensure the right patients are selected for clinical trials.\nThe 12 initial sites that have signed up for participation in the study include Carbone Comprehensive Cancer Center at University of Wisconsin and Holden Comprehensive Cancer Center at University of Iowa Health Care in the US, Assistance Publique-Hôpitaux de Paris and Hospices Civils de Lyon in France, Leipzig University in Germany, Sunnybrook Health Sciences Center in Toronto, Canada, and Shaare Zedek Medic...